Skip to content

Effect of misoprostol and oxytocin in controlling of hemorrhage after cesarean

Comparison of sub-lingual misoprostol and intravenous oxytocin in controlling of hemorrhage after cesarean section.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013080514275N1
Enrollment
100
Registered
2014-03-08
Start date
2013-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum hemorrhage. Postpartum haemorrhage

Interventions

Intervention 1: First group will receive 60 IU oxytocin intravenously (30 units during operation and 30 units during 12 hours after surgery). Intervention 2: Second group will receive 800 micrograms o
Prevention
First group will receive 60 IU oxytocin intravenously (30 units during operation and 30 units during 12 hours after surgery).
Second group will receive 800 micrograms of misoprostol sublingual at the opening time of peritoneum.

Sponsors

Vice Chancellor for Research of Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: singleton pregnant women; elective cesarean delivery; Gravid 1, 2 (maximum one section) Exclusion criteria: Patients with preeclampsia (high blood pressure and protein in the urine); diseases cardiovascular diseases; asthma; uterine rupture; uterine leiomyoma or a women with a history of excessive bleeding after childbirth.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Blood pressure, Heart rate, Shivering, Fever, Nausea and Uterian tone. Timepoint: Each 30 minutes up to 1 hour. Method of measurement: Clinical Assessment.

Secondary

MeasureTime frame
Hematocrite. Timepoint: Before and 24 hours after intervention. Method of measurement: Laboratory value.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Neda Mirjan

Semnan University of Medical Sciences

neda_mirjan@yahoo.com+98 23 1446 0077

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026